아지 바이오파마 보도자료 보도자료 February 22, 2023 Ajinomoto Bio-Pharma Services Successfully Develops Highly Functional Ancestral RNA Ligase 더 읽어보기 January 10, 2023 Ajinomoto and Exelixis Enter Into a License Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer 더 읽어보기 March 3, 2022 Ajinomoto Bio-Pharma Services Awarded Two ‘CMO Leadership Awards’ 더 읽어보기 January 25, 2022 Tony O’Neill Joins Ajinomoto Bio-Pharma Services’ Leadership Team as Vice President of Compliance 더 읽어보기 2021년 5월 25일 아지노모토 바이오-파마 서비스, 새로운 다목적 충전 설비 도입으로 충전·마감 생산 능력 확대 더 읽어보기 March 30, 2021 Ajinomoto Bio-Pharma Services Expands Manufacturing Agreement with AstraZeneca to Include Drug Product Manufacturing 더 읽어보기 March 29, 2021 Ajinomoto Co., Inc. and Bright Peak Therapeutics Inc. Enter into a Research Collaboration and License Agreement to Create Novel Immunocytokines 더 읽어보기 2021년 1월 27일 아지노모토 바이오-파마 서비스와 휴머니젠, 3상 임상시험이 막바지에 접어든 코로나19 치료제 후보물질 ‘렌질루맙’의 충전·포장 공정을 지원하기 위해 제조 계약 범위 확대 더 읽어보기 December 22, 2020 Ajinomoto Bio-Pharma Services and Revance Therapeutics Announce Manufacturing Agreement for Supply of DaxibotulinumtoxinA for Injection 더 읽어보기 October 6, 2020 First Commercial Drug Manufactured via Ajinomoto Bio-Pharma Services’ AJIPHASE Technology Receives FDA Approval 더 읽어보기 September 29, 2020 Ajinomoto Bio-Pharma Services and DNDi Partner to Develop Critical Immunomodulator for Cutaneous Leishmaniasis Therapeutic 더 읽어보기 August 13, 2020 Ajinomoto Bio-Pharma Services Expands Small Molecule Manufacturing Capabilities at its India Facility 더 읽어보기 로딩 중…더 보기
